Back

Merry Life advances TML-6 into global Phase 2 Alzheimer’s study

Verifying
  • Merry Life Biomedical advanced TML-6 into a global Phase 2 Alzheimer’s disease study.
  • 20 clinical sites include nine Taiwan centers, seven Swedish sites and four U.S. centers.
  • Approximately 210 participants will receive TML-6 or placebo daily for 52 weeks.
The information on this website is generated using AI and we cannot guarantee its accuracy. Please use it as reference information only.